New drug confirmed as a potential therapeutic agent for a rare disease, Friedreich's Ataxia

by IRB Lleida. Institut de Recerca Biomèdica

5 days ago
Friedrich's Ataxia, drug, rare disease

A recent study has confirmed the benefits of the drug leriglitazone in treating Friedrich's Ataxia, a rare disease that affects 2-4 people in 100,000 and for which there is currently no effective cure...

Next Stop, the Clinic - Preparing your new Drug for Clinical Research with SciFindern and Formulus®

by CAS, a division of the American Chemical Society

27 days ago
webinar, Drug, SciFindern, Formulus, Clinical Research

Things are going well for your latest drug molecule - it seems efficacious, you have assessed potential toxicity, and even determined a safe starting dose, and now you are ready to move to the clinic...

Sant Pau participates in a phase 2 study that achieves positive results on a drug to combat the cognitive complications of Parkinson’s

by Hospital de la Santa Creu i Sant Pau

1 month ago
Parkinson, cognitive complications, drug

Dr. Kulisevsky, director of the Movement Disorders Unit of the Sant Pau Hospital Neurology Service and head of the Parkinson’s Disease and Movement Disorders Research Group at the Sant Pau Research ...

The drug SAR405, the best inhibitor of autophagy

by IRB Lleida. Institut de Recerca Biomèdica

1 month ago
drug, autophagy, neurological diseases, cancer, UdL, IRBLleida

UdL research questions use of 3-methyladenine in studies because of its toxicity

SOM Biotech announces poster presentation on the repurposing of Eravacycline for the treatment of SARS-CoV-2

by Som Biotech

1 month ago
respiratory disease, Eravacycline, drug, SARS-CoV-2, SOMAIPRO, IDWeek 2020, artificial intelligence

SOM Biotech announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020.

ORYZON publishes paper in Journal of Clinical Oncology demonstrating relevance of iadademstat in leukemia

by Oryzon Genomics

2 months ago
iadademstat, leukemia, drug

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the p...

Metoprolol: an old drug with unique cardioprotective properties

by Centro Nacional de Investigaciones Cardiovasculares - CNIC

2 months ago
metoprolol, drug, cardioprotective, heart attack

CNIC scientists have defined the unique ability if metoprolol to protect the heart during a heart attack

Promega Developing OncoMate™ MSI Assay as Companion Diagnostic for Endometrial Cancer Drug Candidate from Incyte

by Promega Biotech Ibérica

2 months ago
retifanlimab, drug, Endometrial Cancer, MSI, OncoMate

Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte’s anti-PD-1 drug cand...

Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients

by Palobiofarma

3 months ago
clinical trial, drug, asthmatics

The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.

Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis

by Galchimia

3 months ago
drug, visceral leishmaniasis, GlaxoSmithKline, treatments

We are happy to share our latest report from the work carried out in collaboration with GlaxoSmithKline and the Drug Discovery Unit of the University of Dundee. The paper published in RSC Medicinal Ch...

SOM Biotech is awarded a grant from CDTI to start clinical trials with a drug inhibitor of SARS- COV-2 replication

by Som Biotech

3 months ago
grant, CDTI, drug, Eravaciclina, covid-19

SOM Biotechhas been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 h...

Promising drug against non-alcoholic steatohepatitis, a severe type of liver disease

by Fundació Bosch i Gimpera

4 months ago
drug, fatty liver disease, plasma, NASH, non-alcoholic steatohepatitis

Nonalcoholic steatohepatitis (NASH) affects 2 to 5 percent of the world’s population. It is the most severe form of fatty liver disease, which can lead to cirrhosis, among other complications, and i...